BillionToOne Inc. (BLLN) is a Medical Specialities company listed on NASDAQ. In the last 30 days Quantisnow tracked 15 wire items for BLLN, including 9 insider trades, 2 earnings updates and 2 SEC filings. The most recent was published Nov 9, 2026.
BLLN rankings
Financial highlights
Full financials- Revenue, TTM
- $436.87M
- Revenue growth
- +71.9%
- Net income, TTM
- $49.39M
- Net margin
- 11.3%
- Free cash flow, TTM
- $33.90M
- Cash
- $561.51M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks74-8%
2026-05-172026-11-08
Mix4190d
- Insider28(68%)
- Other5(12%)
- SEC Filings4(10%)
- Earnings2(5%)
- Analyst1(2%)
- 13D/G1(2%)
Activity · 52 weeks11564 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13D/A filed by BillionToOne Inc.SCHEDULE 13D/A - BillionToOne, Inc. (0002070849) (Subject)
- INSIDERSEC Form 4 filed by BillionToOne Inc.4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSEC Form 4 filed by BillionToOne Inc.4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Technology Officer Tsao David exercised 20,000 shares at a strike of $2.80 and sold $2,184,854 worth of shares (20,000 units at $109.24) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- SECSEC Form 10-Q filed by BillionToOne Inc.10-Q - BillionToOne, Inc. (0002070849) (Filer)
- SECBillionToOne Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BillionToOne, Inc. (0002070849) (Filer)
- PRBillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue GuidanceMENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2026 and raised guidance for full year 2026. Financial Highlights: Total revenue of $123.0 million in the third quarter of 2026, compared to $83.5 million in the third quarter of 2025, an increase of 47%.Prenatal clinical testing revenue was $104.3 million in the third quarter of 2026, an increase of 41% from the third quarter of 2025.Oncology clinical testing revenue was $17.1 million in the thir
- INSIDERChairman and CEO Atay Oguzhan sold $1,298,000 worth of shares (11,000 units at $118.00) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSEC Form 3 filed by BillionToOne Inc.3 - BillionToOne, Inc. (0002070849) (Issuer)
- PRBillionToOne to Participate in Two Upcoming Investor ConferencesMENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company will participate in two upcoming investor conferences. UBS Global Healthcare Conference 2026Fireside Chat on Tuesday, November 10th at 2:00 PM ET Stifel 2026 Healthcare ConferenceFireside Chat on Wednesday, November 11th at 3:20 PM ET A live and archived webcast of the events will be available on the "Events" page of BillionToOne’s investor relations website at https://investors.billiontoone.com/. About BillionToOne Headquartered in Menlo
- INSIDERSEC Form 4 filed by BillionToOne Inc.4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChairman and CEO Atay Oguzhan sold $1,090,575 worth of shares (11,000 units at $99.14) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChairman and CEO Atay Oguzhan sold $1,823,450 worth of shares (19,334 units at $94.31) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- PRBillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for inte
- INSIDERSEC Form 4 filed by BillionToOne Inc.4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSVP of Laboratory Operations Ten Bosch John Roderick sold $297,995 worth of shares (2,834 units at $105.15) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Technology Officer Tsao David sold $2,162,950 worth of shares (20,000 units at $108.15) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- PRBillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study FindsMENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced the publication of the first peer-reviewed head-to-head study comparing Northstar Response®, a tissue-free, methylation-based liquid biopsy assay utilizing patented single-molecule counting technology to measure the absolute number of circulating tumor DNA (ctDNA) molecules, with a commercially available tumor-informed ctDNA assay for advanced cancer patients undergoing treatment. The study found that Northstar Response tracked disease dynamics on par with or better
- INSIDERChairman and CEO Atay Oguzhan exercised 8,333 shares at a strike of $2.80 and sold $1,326,919 worth of shares (10,999 units at $120.64) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Technology Officer Tsao David exercised 3,333 shares at a strike of $2.80 and sold $416,625 worth of shares (3,333 units at $125.00) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSVP of Laboratory Operations Ten Bosch John Roderick sold $169,920 worth of shares (1,416 units at $120.00) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 22,219 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSVP of Laboratory Operations Ten Bosch John Roderick sold $150,960 worth of shares (1,416 units at $106.61) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 23,635 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDEROfficer Lynch Thomas P. exercised 35,112 shares at a strike of $13.61 and sold $3,873,966 worth of shares (35,112 units at $110.33) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- SECSEC Form 144 filed by BillionToOne Inc.144 - BillionToOne, Inc. (0002070849) (Subject)
- INSIDERChairman and CEO Atay Oguzhan exercised 24,999 shares at a strike of $2.80 and sold $3,030,444 worth of shares (30,331 units at $99.91) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
BLLN FAQ
10 questionsWhat is the latest news on BLLN?
In the last 30 days Quantisnow tracked 15 wire items for BLLN: 9 insider trades, 2 earnings updates, 2 SEC filings and 1 press release or news item. The most recent was published on November 9, 2026.What is BLLN revenue?
BillionToOne Inc. (BLLN) reported $436.87M of revenue for the twelve months ended Sep 30, 2026. That is up 71.9% from the year before. Revenue for fiscal 2025 was $305.11M.Is BLLN profitable?
Yes. BillionToOne Inc. earned $49.39M in net income for the twelve months ended Sep 30, 2026, a net margin of 11.3%.How much cash and debt does BLLN have?
BillionToOne Inc. reported $561.51M in cash and cash equivalents and $88.98M of debt on its most recent balance sheet in SEC filings.Where does BLLN stock trade?
BillionToOne Inc. (BLLN) is listed on NASDAQ.What sector and industry is BLLN in?
BillionToOne Inc. operates in the Health Care sector, Medical Specialities industry.When did BillionToOne Inc. go public?
BillionToOne Inc. (BLLN) completed its IPO in 2025.What are analysts saying about BLLN?
BillionToOne Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $120.00 price target on 2026-09-02. Recent price targets range from $110.00 to $150.00.What companies are similar to BLLN?
Notable peers in the same industry include NTRA (Natera Inc.), CI (The Cigna Group), UNH (UnitedHealth Group Incorporated), HUM (Humana Inc.), ILMN (Illumina Inc.). Compare BLLN side-by-side with any of them on Quantisnow.How can I track BLLN on Quantisnow?
Quantisnow aggregates BillionToOne Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BLLN to receive live email and push alerts on every new disclosure.